Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2022
Companies covered: 10
Tables & Figures: 340
Countries covered: 21
Pages: 200
Download Free PDF

Prostate-Specific Antigen Test Market
Get a free sample of this reportGet a free sample of this report Prostate-Specific Antigen Test Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Prostate-Specific Antigen Test Market Size
Prostate-Specific Antigen Test Market size was valued at USD 3.9 billion in 2022 and is estimated to reach around USD 8.8 billion by 2032. The ongoing research in the field of prostate cancer diagnostics and therapy has resulted in the development of more advanced testing and prostate cancer treatment devices. These advancements increase the effectiveness of Prostate-specific antigen (PSA) testing for early detection and monitoring.
Furthermore, with the aging population expanding and the notable prevalence of prostate cancer among older males, it is anticipated that the market will experience substantial growth in the coming years. According to a publication in the World Journal of Oncology, prostate cancer affects approximately 1 in 350 males under the age of 50, with the incidence rate increasing to 1 in every 52 men between the ages of 50 and 59. Among men over the age of 65, the incidence rate soars to nearly 60%. As the elderly population continues to grow, there will be a rising number of individuals at an elevated risk of prostate cancer. Consequently, this will lead to an increased demand for PSA testing.
The prostate-specific antigen test is a diagnostic blood test that quantifies the bloodstream's concentration of PSA, a protein secreted by the prostate gland.